


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-0.90%
+9.19%
+2.92%
+2.30%
-1.97%
AXSM
Axsome Therapeutics
$188.02
Strengths

Upgraded on attractively valued
AXSM Price Performance
$148.79 (+26.37%)
$134.99 (+39.28%)
$124.41 (+51.13%)
$131.55 (+42.93%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future
![]()
AXSM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
AXSM Street Sentiment is extremely bullish and have positive views on the near-term outlook
AXSM has Low risk level

Average key support and resistance price levels
AXSM
Axsome Therapeutics
188.02
+1.90%
CNET
ZW Data Action
1.24
-3.51%
NCTY
The9 Limited America
6.87
-3.38%
WB
10.84
-0.46%
ATER
Aterian
0.72
0.00%
What is AXSM current stock price?
What are AXSM stock strengths?
What is AXSM Risk Level?
What is AXSM market cap and volume?
What is AXSM current Stock IQ?
Should I buy AXSM stock right now?
Is AXSM a Strong Buy right now?
What does a 'Strong Buy' rating mean for AXSM?
What does a 'Strong Sell' rating mean for AXSM?
What factors influence AXSM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-0.90%
+9.19%
+2.92%
+2.30%
-1.97%
AXSM
Axsome Therapeutics
Current Price
$188.02
Stock Insights
Strengths

Upgraded on attractively valued
Recently Viewed
AXSM
Axsome Therapeutics
188.02
+1.90%
CNET
ZW Data Action
1.24
-3.51%
NCTY
The9 Limited America
6.87
-3.38%
WB
10.84
-0.46%
ATER
Aterian
0.72
0.00%

AXSM Price Performance
$148.79 (+26.37%)
$134.99 (+39.28%)
$124.41 (+51.13%)
$131.55 (+42.93%)
AXSM Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future
![]()
AXSM Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
AXSM Street Sentiment is extremely bullish and have positive views on the near-term outlook
AXSM has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 04, 2025
Reiterate
Buy
Needham
Oct 21, 2025
Reiterate
Overweight
Morgan Stanley
Oct 02, 2025
Reiterate
its Overweight
Piper Sandler
Oct 02, 2025
Initiate
Buy
B. Riley
AXSM Stock IQ
AXSM Latest Analysis
Piper Sandler ish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30. Axsome Therapeutics Inc. (NASDAQ:AXSM) is one of the best mid-cap growth stocks to buy right now. On January 16 Piper Sandler raised its price target on Axsome Therapeutics to $223 from $148 with an Overweight rating. Piper Sandler is confident in Auvelitys commercial potential particularly given the highly likely FDA label expansion into Alzheimers agitation [….]
Fri Jan 23, 2026
Why Axsome Therapeutics (AXSM) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Thu Jan 15, 2026
Axsome Therapeutics (AXSM) Price Target Increased by 13.75% to 207.38. The average one-year price target for Axsome Therapeutics (NasdaqGM:AXSM) has been revised to $207.38 / share. This is an increase of 13.75% from the prior estimate of $182.31 dated December 18 2025. The price target is an average of many targets provided by
Wed Jan 14, 2026
Axsome Therapeutics Preliminary Q4 Net Product Revenue Up 65% . (RTTNews) - Axsome Therapeutics Inc. (AXSM) said based on preliminary financial information Axsome expects total product revenue to be approximately $196.0 million for the fourth quarter representing 65% annual growth compared to the fourth quarter 2024. The company expects t
Mon Jan 12, 2026
Axsome Therapeutics announces prelim Q4 FY revenue above estimates.
Mon Jan 12, 2026
2 Healthcare Stocks to Buy for 2026 and Beyond. Key PointsAxsome Therapeutics and Exelixis are generating solid revenue with their current lineups.
Thu Jan 8, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
AXSM Stock trends
AXSM Stock performance
AXSM Stock analysis
AXSM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.